Introduction
============

After a decade of increases in financing for HIV services in low-income and middle-income countries (LMICs), funding has levelled off \[[@R1]\]. In this context, to scale up HIV services, countries must optimize use of available funds \[[@R2]--[@R4]\]. Empirical data on the per person cost of HIV services are critical to making better use of resources; they can be used to assess the cost-effectiveness of services, model the cost and impact of alternative approaches, and identify and address inefficiencies.

There is a growing body of information on the unit cost of evidence-based HIV services in sub-Saharan Africa including HIV testing and counselling (HTC) and the prevention of mother-to-child transmission (PMTCT) \[[@R5]\]. Previous studies have assessed the cost of client-initiated and provider-initiated HTC in facilities \[[@R6]--[@R17]\]. A few studies have examined the facility-level cost of PMTCT \[[@R7],[@R18]--[@R23]\]. However, with few exceptions \[[@R14],[@R15]\], existing empirical HTC and PMTCT cost data focus on one step of the service cascade -- cost per person tested for HTC and cost per woman or per mother--baby pair receiving antiretroviral prophylaxis for PMTCT. These studies do not provide the cost data along service cascades that are critical for identifying and addressing implementation inefficiencies.

In this article, we estimate the average cost per client along the HTC component of the HIV treatment and care cascade \[[@R24]\], which we refer to as the HTC cascade and several steps along the PMTCT cascade \[[@R25]\] across a range of facilities in Kenya, Rwanda, South Africa, and Zambia. We use data from the 'Optimizing the Response in Prevention: HIV Efficiency in Africa' (ORPHEA) study \[[@R26]\] -- a cross-sectional, micro-costing study conducted from 2012 to 2013 to assess the cost, cost structure, cost variability, and efficiency determinants of HIV prevention interventions.

Methods
=======

The ORPHEA study methods and tools have been described in detail elsewhere \[[@R26]\], and only those relevant to this analysis are summarized here.

Study sample
------------

Kenya, Rwanda, South Africa, and Zambia were purposively selected to reflect a range of contextual factors, HIV burden, and HIV prevention intervention coverage levels \[[@R26]\]. For each country, multistage sampling was used to first randomly select subnational areas and then select facilities providing at least one of the following services: HTC, PMTCT, or voluntary medical male circumcision (the latter not reported here). Health facilities in selected subnational areas were enumerated along with information on the services of interest stratified by ownership/management (e.g. owned/managed by government or nongovernment organizations) and level of service provision (e.g. hospitals and primary care clinics). Facilities were randomly sampled within these strata using probability proportional to size, with preference given to integrated sites providing more than one service of interest. A replacement sample was also generated prior to study initiation to systematically substitute facilities in which either services of interest were not provided or service providers declined to participate. Although refusal rates were close to 0 in all countries, replacement sites were included in Kenya when services were found not to be provided in the original sample. The analytic facility samples are shown in Table [1](#T1){ref-type="table"}.

Services studied
----------------

*HTC:* The HTC approaches for which costs were estimated were those implemented in sampled facilities at the time of the study: a mix of client-initiated and provider-initiated HTC \[[@R27]\]. The HIV testing algorithms studied were those in place at the time of the study -- all countries used serial rapid HIV test algorithms with laboratory ELISA used to resolve discordant results.

*PMTCT:* The following PMTCT components were assessed: HTC, routine clinical monitoring, and provision of antiretroviral and other drugs to mothers and infants. The prophylactic regimens considered were those implemented at the time of the study. In Kenya, South Africa, and Zambia Option A was used, in Rwanda Options B and B+ were implemented (eTable 1) \[[@R28],[@R29]\].

Ethical clearance
-----------------

The study was approved by the ethical review boards at the following institutions: National Institute of Public Health, Mexico; Kenyatta National Hospital and University of Nairobi; Northeastern University in Boston; Rwanda Biomedical Center; University of the Witwatersrand in Johannesburg; and University of Zambia \[[@R26]\].

Data collection
---------------

A standardized set of survey instruments were implemented to collect information comparable across countries \[[@R26]\] with data collection staggered by country from October 2012 to December 2013.

Data were collected retrospectively from facility-level and district-level databases, programme records, and reports by month for the calendar year prior to data collection (i.e. 2011 and 2012). Study instruments were designed to assemble information on five cost categories: personnel, recurrent inputs and services, capital (equipment and vehicle operating costs), training, and supervision (staff opportunity costs corresponding to duration of these activities) (eTables 2 and 3, providing information on salaries and input prices). We collected cost data irrespective of funding source, and donated inputs were valued at their opportunity costs determined by local market prices, adopting an economic costing perspective \[[@R30]\].

Time motion \[[@R31],[@R32]\] was implemented at integrated facilities. To assess the contribution of staff for each service in integrated sites, data collectors randomly selected and observed up to six providers per site during different time periods to reflect a representative sample of days, hours, and providers. Data were collected on type and duration of activities, including time spent on administrative work, meetings, and breaks for 3--4 continuous hours. For each multitasking provider observed, time spent with patients for each intervention was assigned to that intervention, and all other noncontact productive time (e.g. administrative work and meetings) was divided equally across the provider\'s reported service areas. Weights were calculated on the basis of observed staff and applied to all multitasking staff based on provider type and participation across different combinations of services studied. When staff worked on only one service and in facilities where all staff worked on only one service, all effort was allocated to that service.

We collected output data from facility records and from district health information systems -- when they were not available at facilities. We gathered information on multiple outputs, corresponding to the following steps along the HTC and PMTCT service cascades, respectively: clients tested and clients diagnosed as HIV-positive; and clients tested, clients diagnosed as HIV-positive, HIV-positive clients receiving antiretroviral prophylaxis, and infants born to HIV-positive clients receiving nevirapine (NVP) (eMethods 1 and 2, providing details on output construction).

Cost estimation
---------------

We estimated costs from the perspective of service providers using a micro-costing approach in which quantity and unit price of essential inputs were assessed along with information on outputs \[[@R30]\]. Total annual costs were calculated for each facility intervention. Costs of personnel, recurrent inputs and services, capital, training, and supervision were aggregated for the year of observation for each intervention as follows: 

where   denotes the total annual cost of intervention *j* (1 = HTC and 2 = PMTCT) at facility *k*. The term   denotes the annual cost of input category *i* (1 = personnel, 2 = recurrent inputs and services, 3 = capital, 4 = training, and 5 = supervision) for intervention *j* at facility *k*.

We estimated the average cost per facility intervention as follows: 

where   denotes the average cost per output along the cascade for HTC and PMTCT (*j* = 1 or 2);   denotes outputs along the cascade where 1=1 for clients tested, 1=2 for clients tested and HIV-positive, 1=3 for HIV-positive clients receiving antiretroviral prophylaxis, and 1=4 for infants born to HIV-positive clients receiving NVP -- with the latter two only defined for PMTCT. According to the service cascade definition,   for HTC and   for PMTCT.

For integrated facilities, shared inputs were apportioned across interventions. For recurrent services, capital, training, and supervision, we weighted input annual costs by the annual number of clients per intervention over the total annual number of outpatient clients in the facility. The result was the estimated annual costs allocated to each intervention. Also, as indicated above, to allocate personnel costs across interventions, we applied weights derived from the time motion component.

All cost data were converted from local currencies to United States dollars (US\$) using mid-year exchange rates for 2011 (Kenya: 88.81 Kenyan shillings and Zambia: 4860.7 Zambian kwacha) and 2012 (Rwanda: 614.3 Rwandan francs and South Africa: 8.21 South African rand), and then inflated to 2013 prices. We report both unadjusted costs and costs adjusted for purchasing power parity (PPP) for nontradable services, primarily staff salaries.

Results
=======

Facility characteristics and average annual outputs
---------------------------------------------------

*HTC:* Of the 230 facilities in the HTC sample, 160 were primary care facilities, 67 were secondary hospitals, and three were tertiary sites with over two-thirds managed by government (Table [1](#T1){ref-type="table"}). The average annual number of HTC clients per site varied from 1491 (Zambia) to 6610 (Rwanda). HTC clients constituted from 16.2% (Zambia) to 35.4% (Rwanda) of outpatient clients, and the average HTC HIV-positivity rate was 1.6, 11.6, 19.5, and 21.3% in Rwanda, Kenya, Zambia, and South Africa, respectively.

*PMTCT:* Of the 212 facilities in the PMTCT sample, 155 were primary care facilities, 54 were secondary centres, and three were tertiary facilities with over two-thirds managed by government (Table [1](#T1){ref-type="table"}). The average annual number of antenatal care (ANC) clients per site ranged from 835 (Rwanda) to 1027 (Zambia). The average PMTCT HIV-positivity rate was 1.7, 10.1, 12.2, and 17.4% in Rwanda, Zambia, Kenya, and South Africa, respectively. PMTCT clients tested for HIV as a proportion of ANC clients ranged from 33.4% (Kenya) to 97.3% (Rwanda). PMTCT clients receiving antiretrovirals for PMTCT as a percentage of ANC clients diagnosed HIV-positive ranged from 73.7% (Zambia) to 91.5% (Kenya). Infants receiving NVP as a proportion of PMTCT clients receiving antiretrovirals for PMTCT ranged from 89.1% (Zambia) to 98.8% (Rwanda).

Average unit costs along the service cascades
---------------------------------------------

*HTC:*Table [2](#T2){ref-type="table"} presents the average unit costs for each cascade step using the full sample of facilities for which unit costs could be estimated. The average cost per HTC client tested ranged from US\$5 (SD US\$7) in Rwanda to US\$31 (SD US\$24) in South Africa, whereas the average cost per HTC client diagnosed as HIV-positive ranged from US\$122 (SD US\$119) in Zambia to US\$1367 (SD US\$2093) in Rwanda. Table [2](#T2){ref-type="table"} illustrates that variation in these costs also existed within countries. Median unit costs were lower than average unit costs, revealing a skewed distribution of per client costs with some facilities having high costs. This within-country cost variation is further illustrated in Fig. [1](#F1){ref-type="fig"}, which displays the average cost per HTC client tested by facility type. We did not find differences in the average cost per HTC client tested by facility ownership.

![Average cost per client tested for HIV testing and counselling and prevention of mother-to-child transmission by facility type.](aids-30-2495-g009){#F1}

The within country differences between the average cost per HTC client tested and the average cost per HTC client diagnosed as HIV-positive were associated with the positivity rates in the HTC samples (Fig. [2](#F2){ref-type="fig"}). The difference was the largest in Rwanda where the HIV-positivity rate was 1.6%, almost half the national prevalence.
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As regards between country differences, after adjusting for differences in prices using PPP-adjusted dollars, the average cost per HTC client tested in Rwanda and Kenya was significantly lower than in South Africa (*P* \< 0.01) and Zambia (*P* \< 0.01), and the average cost per HTC client diagnosed as HIV-positive was significantly higher in Rwanda than in the other three countries (*P* \< 0.01).

*PMTCT:* The average annual cost per PMTCT client tested ranged from US\$18 (SD US\$20) in Rwanda to US\$89 (SD US\$56) in South Africa (Table [2](#T2){ref-type="table"}). The average cost per PMTCT client diagnosed as HIV-positive ranged from US\$565 (SD US\$584) in Zambia to US\$2021 (SD US\$3210) in Rwanda. The average cost per PMTCT client receiving antiretrovirals ranged from US\$704 (SD US\$610) in South Africa to US\$2314 (SD US\$3204) in Rwanda. The average cost per infant receiving NVP ranged from US\$888 (SD US\$884) in South Africa to US\$2359 (SD US\$3257) in Rwanda. Note that these average annual costs were estimated using different sample sizes along the PMTCT service cascade due to missing values for some output indicators (eTable 4, providing the average unit costs for the subset of facilities for which unit costs could be estimated at every step of the PMTCT cascade). As with the costs along the HTC cascade, Table [2](#T2){ref-type="table"} displays considerable variation within countries in the average costs along the PMTCT service cascade. This within-country cost variation is further illustrated in Fig. [1](#F1){ref-type="fig"}, which displays the average cost per PMTCT client tested by facility type. We did not find differences in the average cost per PMTCT client tested by facility ownership.

As with the costs along the HTC cascade, the differences between the average cost per PMTCT client tested and the average cost per PMTCT client diagnosed as HIV-positive were closely associated with the PMTCT positivity rate and the largest in Rwanda (Fig. [2](#F2){ref-type="fig"}). In contrast, the difference between the average cost per PMTCT client tested and diagnosed as HIV-positive and the average cost per client receiving antiretroviral prophylaxis was the smallest in Rwanda and the largest in Kenya.

In terms of the between-country differences, when adjusting for differences in prices, the average cost per PMTCT client tested in Rwanda was significantly lower than in Kenya (*P* \< 0.01), South Africa (*P* \< 0.01), and Zambia (*P* \< 0.05), and the average cost per PMTCT client diagnosed as HIV-positive was significantly higher in Rwanda than in South Africa (*P* \< 0.01) and Zambia (*P* \< 0.05).

Distribution of costs
---------------------

Staff costs comprised the majority of costs for both interventions in Kenya, South Africa, and Zambia (Fig. [3](#F3){ref-type="fig"}). Supplies -- with HIV test kits as the main contributor -- made up the second largest shares of HTC costs in these countries, and drugs made up the second largest proportion of PMTCT costs. In Rwanda, although the pattern for PMTCT was similar to that in the other countries, for HTC, staff costs made up a smaller proportion of total HTC costs, and the proportions of staff and supply costs were almost equivalent.
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Figure [3](#F3){ref-type="fig"} also shows the average number of full-time equivalent staff for each intervention in the four countries. Other health staff, comprising mostly of counsellors, represented an important HTC provider category for Kenya, South Africa, and Zambia, whereas nurses dominated the provision of HTC in Rwanda. In contrast, the cost of PMTCT service provision was dominated by nursing costs in all countries.

Discussion
----------

The current cost analysis of HTC and PMTCT services in Kenya, Rwanda, South Africa, and Zambia is unique in its focus on estimating costs along the service cascades of these two interventions. It also represents one of the most comprehensive, multicountry assessments of HTC and PMTCT service delivery costs. The sample size was large compared with similar studies, and data were collected using robust standardized methods and tools yielding comparable information across facilities within and across countries.

We found between-country differences in the first and second steps of the HTC and PMTCT cascades; in general, after adjusting for differences in prices, the average cost per client tested was lower in Rwanda, whereas the average cost per client diagnosed as HIV-positive was higher for both HTC and PMTCT. We also observed substantial variation in the unit costs of HTC and PMTCT within facility types in South Africa, Kenya, and Zambia and to a lesser extent among primary care facilities in Rwanda (only one hospital included in the sample) suggesting the existence of implementation inefficiencies. Staff costs were the most important driver of HTC and PMTCT service delivery costs in all countries except Rwanda where staff costs made up the majority of PMTCT costs but less than half of HTC costs. Cross-country salary differences -- even after controlling for purchasing power -- were a determinant of the cross-country unit cost variation; average salaries for all provider types were significantly higher in South Africa, whereas salaries for nurses were significantly lower in Rwanda, for example. Also relevant to the cross-country differences in unit costs and cost compositions were the variations in the services delivered and the staff categories delivering services. Nurses dominating HTC provision in Rwanda in contrast to counsellors dominating HTC provision in the other countries is likely explained by the prevalence of provider-initiated testing in Rwanda at the time of the study compared with the pervasiveness of client-initiated HTC in the other countries. Similarly, for PMTCT, the larger proportion of antiretroviral costs in Rwanda was due to the fact that Rwanda was the only country implementing Options B and B+ at the time of data collection.

We found unit cost heterogeneity along the HTC and PMTCT cascades within countries. Specifically, there were large differences between the unit costs of the first and second steps of the HTC cascade within each country, although the difference was the largest in Rwanda. Although average cost per person tested was the lowest in Rwanda, average cost per person testing positive was the highest. This difference was driven by the low positivity rate in the Rwandan sample; in Rwanda, many more people were tested to diagnose one person living with HIV. This finding suggests that efficiency gains could be made by better targeting HTC services to populations at risk for HIV infection. Unfortunately, we did not collect data on whether positive tests were first-time tests or repeat tests and therefore cannot determine the cost of identifying new HIV cases. Given the high levels of coverage of HTC and antiretroviral treatment achieved in Rwanda \[[@R33]\], the high cost per person diagnosed may also reflect the increasing marginal cost of finding new HIV cases as HTC coverage expands.

For PMTCT, we found differences between the unit costs of the first and second steps, and the difference was the largest in Rwanda. We also observed large differences between the unit costs of the second and third steps, which provide insights into the linkages of HIV-positive women to prophylaxis and care and are underpinned by retention along the cascade within given facilities. The difference between the second and third steps was greater in Kenya, where less than half the women identified as positive received antiretroviral prophylaxis in the facilities where they were tested; followed by women in Zambia, where the equivalent figure was roughly three quarters. Though we were unable to identify whether women received antiretroviral drugs in another facility as previous studies have done \[[@R34]--[@R38]\], our findings raise concerns about potentially large losses along the PMTCT cascade most markedly in Kenya and Zambia.

When compared with prior studies that assessed both, the average costs per HTC client tested in our study were similar to those found in prior studies, whereas the average costs per client diagnosed HIV-positive were somewhat higher \[[@R14],[@R15]\]; we are not aware of similar studies conducted for PMTCT. In a previous study that collected data for 2008--2009 in Kenya and Swaziland, unit cost per client tested was between US\$6 and 9, whereas unit cost per client diagnosed as HIV-positive ranged from US\$47 to 110 \[[@R15]\]. In a study that collected data from 2003 to 2005 in Uganda, facility-based HCT costs ranged between US\$12 and 19 and US\$43 and 101 per client tested and client diagnosed HIV-positive, respectively. Most of the distinctions are probably due to differences in facility-level positivity rates. Other likely contributing factors are variations in health systems set-up and distinctions in indicator definitions and methods used. Our study is the only one that used time motion direct observation methods to assess staff time use, the dominant cost component of these interventions.

The following limitations should be considered when interpreting our findings. Though our study is unique in its focus on multiple steps along the HTC and PMTCT service cascades, there are some shortcomings. The study did not capture data on the critical step following HIV diagnosis: linkage and enrolment in care \[[@R24]\]. We were also unable to capture details on monitoring and quality assurance. Though systematic sampling was used, the selected samples are unlikely to be nationally representative as subnational areas were purposefully selected to represent in-country variation in HIV epidemics. Because we retrospectively collected information on inputs, costs, and outputs, staff observations were made subsequent to the period studied, although never more than 12 months later. We used routine monitoring data to capture information on outputs, and the detail, quality, and completeness of these data varied. Our inability to distinguish between client-initiated and provider-initiated HTC is one drawback of the information used. Every effort was made to capture staff costs as accurately as possible through time-motion methods that sought to be as inconspicuous as feasible; however, there are limitations to these methods including the potential bias introduced by the observer effect as well as the possibility that the days and hours of staff moments monitored were not representative of the entirety of staff moments in a given year \[[@R32]\].

In conclusion, we found important differences in unit costs along the HTC and PMTCT service cascades within and between countries. Although variation in service quality might explain some of this heterogeneity, it is unlikely that the magnitude of differences observed can be explained by differences in service quality alone. Rather, this cost variation suggests that substantial efficiency gains could be made in delivering these services in all countries studied whether by better targeting services, altering who delivers services, or changing the way services are delivered. To provide guidance to policymakers, we are undertaking further work to assess the determinants of this cost variation.
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###### Supplemental Digital Content

###### 

Sample sites by ownership and facility type and key cascade indicators.

  Countries                                                               Kenya   Rwanda   South Africa   Zambia                         
  ----------------------------------------------------------------------- ------- -------- -------------- -------- ------ ------- ------ -------
  Random sample of sites                                                  HTC     PMTCT    HTC            PMTCT    HTC    PMTCT   HTC    PMTCT
   Tertiary hospitals                                                     1       2                                2      1              
   Secondary hospitals                                                    30      31       1              1        23     10      13     12
   Health centres                                                         15      17       52             52       13     13      42     42
   Other primary care facilities[^a^](#TF1-1){ref-type="table-fn"}        10      7                                23     20      5      4
   Total                                                                  56      57       53             53       61     44      60     58
  Ownership                                                                                                                              
   Public                                                                 29      37       29             29       52     36      52     51
   Private[^b^](#TF1-2){ref-type="table-fn"}                              27      20       24             24       9      8       8      7
  Cascade indicators                                                                                                                     
   Average annual number of clients tested                                4235    864      6610           835      4784   989     1491   1027
   Average % of total patients tested[^c^](#TF1-3){ref-type="table-fn"}   30.2    33.4     35.4           97.3     16.9   43.1    16.2   60.2
   Average % of clients diagnosed HIV-positive                            11.6    12.2     1.6            1.7      21.3   17.4    19.5   10.1
   Average % of clients receiving ARV prophylaxis                         NA      91.5     NA             86.3     NA     83.3    NA     73.7
   Average % of infants receiving NVP prophylaxis                         NA      96.1     NA             98.8     NA     98.0    NA     89.1

ARV, antiretroviral; HTC, HIV testing and counselling; NVP, nevirapine; PMTCT, prevention of mother-to-child transmission.

^a^Other primary care facilities include the following facilities: in Kenya -- dispensaries, medical clinics, and mobile clinics; in South Africa -- medical clinics; and in Zambia -- health posts.

^b^Private facilities are not-for-profit institutions operated by faith-based and other nongovernmental organizations.

^c^For HTC, the denominator is the total annual number of outpatient clients; for PMTCT the denominator is the total annual number of antenatal care clients.

###### 

Average annual unit costs along the HIV testing and counselling and prevention of mother-to-child transmission service cascades (United States dollars).

                                                                                Kenya   Rwanda   South Africa   Zambia                                                                                                    
  ----------------------------------------------------------------------------- ------- -------- -------------- -------- ------ ---- ------ ------ ------ ------ ---- ------ ------ ----- ------ ---- ------ ------ ----- ------
  HTC                                                                                                                                                                                                                     
   Average cost per HTC client tested                                           56      7        7              5        7      53   5      7      3      5      61   31     24     21    31     60   19     19     13    13
   Average cost per HTC client diagnosed HIV-positive                           56      146      318            55       80     53   1367   2093   591    1057   59   173    157    126   177    58   122    119    90    85
   Average cost per HTC client tested (PPP)[^b^](#TF2-2){ref-type="table-fn"}   56      15       16             9        12     53   9      13     4      8      61   43     36     26    43     60   35     35     24    23
   Average cost per HTC client diagnosed HIV-positive (PPP)                     56      291      692            102      146    53   1976   2679   735    1558   59   243    240    161   250    58   222    225    164   153
  PMTCT                                                                                                                                                                                                                   
   Average cost per PMTCT client tested                                         57      59       84             35       49     53   18     20     11     16     44   89     56     81    99     58   49     71     30    35
   Average cost per PMTCT client diagnosed HIV-positive                         51      673      1037           256      776    53   2021   3210   1159   1582   42   567    417    469   509    56   565    584    402   360
  Average cost per PMTCT client receiving ARV prophylaxis                       31      1385     3750           275      1262   53   2314   3204   1393   1868   34   704    610    528   765    39   894    1117   483   535
   Average cost per infant receiving NVP prophylaxis                            26      1329     3965           304      1112   51   2359   3257   1393   1887   10   888    884    462   1085   32   1072   1229   529   650
   Average cost per PMTCT client tested (PPP)                                   57      130      197            71       106    53   34     42     19     29     43   125    81     118   146    58   89     132    55    61
   Average cost per PMTCT client diagnosed HIV-positive (PPP)                   51      1456     2323           544      1671   53   3943   6807   1830   3042   41   803    627    688   749    56   1025   1105   683   640
   Average cost per PMTCT client receiving ARV prophylaxis (PPP)                31      3041     8587           540      2735   53   4496   6806   2546   3568   34   1031   942    757   1120   39   1618   2112   844   944
   Average cost per infant receiving NVP prophylaxis (PPP)                      26      2921     9109           605      2404   51   4581   6922   2546   3600   10   1290   1364   607   1599   32   1936   2325   925   1125

ARV, antiretroviral; HTC, HIV testing and counselling; *n*, sample size; NVP, nevirapine; PMTCT, prevention of mother-to-child transmission; PPP, purchasing power parity; Wt mean, weighted mean; Unit costs in 2013 US\$.

^a^Weighted mean represents a nationally representative average value, taking into account the relative contribution of each facility in terms of its patient volume. It was calculated as the summation of each data point multiplied by a nonnegative weight (defined as the number of annual HTC clients/outpatient health clients). Therefore, data points with a higher weight contribute more to the weighted mean than do elements with a low weight.

^b^Staff costs (nontradable inputs) were adjusted for purchasing power parity differences between countries using 2013 World Bank Data (*source:* <http://data.worldbank.org/indicator/PA.NUS.PPP>).
